Can you walk me through what the treatment schedule and monitoring plan would look like with the intermittent...

For intermittent androgen deprivation therapy (ADT) in prostate cancer, the treatment schedule and monitoring plan typically follows this general approach, according to NCCN Guidelines:

During the "on" treatment period:

• ADT is administered continuously, either via injections or oral medications, to suppress testosterone levels.
• PSA levels are checked every 3-6 months to monitor treatment response.
• Testosterone levels may be measured to ensure adequate suppression.
• Imaging (e.g., CT, bone scan) is performed if symptoms or PSA levels suggest disease progression.
• The "on" period usually lasts 6-12 months, or until a maximal PSA response is achieved (e.g., PSA <0.2 ng/mL).

During the "off" treatment period:

• ADT is stopped, allowing testosterone levels to recover.
• PSA is monitored every 3 months.
• When PSA rises to a predetermined threshold (often 10 ng/mL, but can vary), the next "on" treatment cycle begins.
• The length of the "off" period is variable, ranging from a few months to a few years.

The American Urological Association (AUA) guidelines note that the precise PSA level to restart ADT is still uncertain, but is commonly between 4-10 ng/mL. They recommend individualizing this based on PSA doubling time, initial response to ADT, and patient preference.

Bone density scans may be done every 1-2 years to monitor for osteoporosis, a side effect of ADT. The NCCN also advises screening and treatment for other ADT side effects like diabetes, cardiovascular disease, and sexual dysfunction.

As always, discuss your specific treatment plan and monitoring schedule with your oncologist, as they may tailor recommendations based on your individual case. Let me know if you have any other questions!